CHI Webinar – Aug 25th, 2022: Assessing neuraminidase presence in influenza vaccines using InDevR’s VaxArray Platform
Speaker: Jeff Pederson, Ph.D.
Title: Global Head, Analytical Science and Technology, Seqirus
Bio: Jeff Pederson is the Global Head, Analytical Science and Technology (AS&T) for Seqirus. He is responsible for leading the AS&T organization in all analytical activities related to commercial Influenza vaccine manufacturing. He provides technical and strategic direction for the advancement of industry-leading analytics supporting the Seqirus Influenza vaccine business. This includes innovation, method development and validation, and transfer activities. Prior to Seqirus, Jeff was Vice President of Quality at KBI Biopharma. He started his career at Wyeth, where he held various roles of increasing responsibility within process and analytical development. Jeff earned his Ph.D. in Genetics from North Carolina State University, a B.S. in Biology from Virginia Tech; he completed his postdoctoral training at the University of Wisconsin.
Speaker: Kurt Marshall, Ph.D.
Title: Application Scientist
Bio: Kurt Marshall earned a B.S. in Biology from the University of Virginia, M.S. in Integrative Physiology from the University of Colorado – Boulder, and a Ph.D. in Biomedical Sciences from the University of Missouri. His background includes both customer facing and R&D roles supporting and developing novel gene editing tools and reagents. More recently, Kurt worked in gene therapy process development and cell therapy early research. He enjoys skiing and biking, but these have taken a back seat to his new favorite activity of spending time with his 18-month-old son, Caleb.
About This Webinar
Sponsored by: InDevR, Inc. in collaboration with Seqirus, A CSL Company
The quantity, quality, and structure of neuraminidase (NA) is not currently regulated in flu vaccines. However, the presence of immunogenic forms of NA must be confirmed during vaccine production using a “suitable enzymatic or immunological” method [Ph. Eur. Monograph 0869; WHO 927, 2005]. The confirmation of NA presence in flu vaccines is most often accomplished by measuring the enzymatic activity of NA. Importantly, the lack of a uniform assay and standards have been identified as impediments to standardized assessment of NA flu vaccine content. Current non-enzymatic NA assays are problematic as they are limited to measuring specific strains or not stability indicating. VaxArray Assays, which correlate with NA activity, offers several advantages over the enzymatic assay for identification of NA. This presentation will highlight the use of the VaxArray Assay, a multiplexed, stability-indicating, sandwich immunoassay, as an identification assay for influenza vaccines. After an introduction to influenza vaccines and consideration of the current neuraminidase assays, the development and validation of the VaxArray Platform will be presented. The VaxArray Influenza Seasonal Neuraminidase Potency Assay can be used to confirm the presence of subtype-specific neuraminidase (NA) in flu vaccines. Future characterization and quantification of neuraminidase will also be discussed.
Learn the importance of testing for neuraminidase presence in influenza vaccines and best methods for evaluating not only the identity, but also stability of NA. Save time and get more consistent results for your neuraminidase / Influenza vaccine analysis by learning new techniques which can replace or complement current laborious and lengthy tests. Run your assay in hours instead of days, with better consistency across departments and sites using the VaxArray kits.
Learn How To:
Quickly identify presence of immunogenic forms of NA.
Measure NA stability in about an hour.
Enable lab-to-lab consistency.